Prognostic value of blood urea nitrogen in patients hospitalized with worsening heart failure: insights from the Acute and Chronic Therapeutic Impact of a Vasopressin Antagonist in Chronic Heart Failure (ACTIV in CHF) study.
暂无分享,去创建一个
Gerasimos Filippatos | David D Shin | David D. Shin | C. O'connor | G. Filippatos | D. Lloyd‐Jones | M. Gheorghiade | K. Adams | J. Ouyang | C. Orlandi | W. G. Stough | Donald M Lloyd-Jones | Mihai Gheorghiade | Cesare Orlandi | Wendy Gattis Stough | J. Rossi | Kirkwood F Adams | John Ouyang | Joseph Rossi | Christopher O'connor
[1] P. Doevendans,et al. Renal function; , 2004 .
[2] J. Cohn,et al. Neurohumoral control mechanisms in congestive heart failure. , 1981, American heart journal.
[3] A. Burger,et al. Effect of elevated admission serum creatinine and its worsening on outcome in hospitalized patients with decompensated heart failure. , 2004, The American journal of cardiology.
[4] Peter C. Austin,et al. Predicting mortality among patients hospitalized for heart failure: derivation and validation of a clinical model. , 2003, JAMA.
[5] Doron Aronson,et al. Elevated blood urea nitrogen level as a predictor of mortality in patients admitted for decompensated heart failure. , 2004, The American journal of medicine.
[6] K. Furie,et al. Heart disease and stroke statistics--2008 update: a report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. , 2007, Circulation.
[7] C. O'connor,et al. Rationale and study design for a multicenter, randomized, double-blind, placebo-controlled study of the effects of tolvaptan on the acute and chronic outcomes of patients hospitalized with worsening congestive heart failure. , 2003, American heart journal.
[8] C. O'connor,et al. Organized Program to Initiate Lifesaving Treatment in Hospitalized Patients with Heart Failure (OPTIMIZE-HF): rationale and design. , 2004, American heart journal.
[9] C. O'connor,et al. Effects of Tolvaptan, a Vasopressin Antagonist, in Patients Hospitalized with Worsening Heart Failure: A Randomized Controlled Trial , 2004 .
[10] K. Adams,et al. Characteristics and outcomes of patients hospitalized for heart failure in the United States: rationale, design, and preliminary observations from the first 100,000 cases in the Acute Decompensated Heart Failure National Registry (ADHERE). , 2005, American heart journal.
[11] M. Domanski,et al. The prognostic implications of renal insufficiency in asymptomatic and symptomatic patients with left ventricular systolic dysfunction. , 2000, Journal of the American College of Cardiology.
[12] W John Boscardin,et al. Risk stratification for in-hospital mortality in acutely decompensated heart failure: classification and regression tree analysis. , 2005, JAMA.
[13] B. Massie,et al. The clinical challenge of cardiorenal syndrome. , 2004, Circulation.
[14] W. Abraham,et al. Hormones and hemodynamics in heart failure. , 1999, The New England journal of medicine.
[15] C. O'connor,et al. The prognostic importance of different definitions of worsening renal function in congestive heart failure. , 2002, Journal of cardiac failure.
[16] R. Califf,et al. Short-term intravenous milrinone for acute exacerbation of chronic heart failure: a randomized controlled trial. , 2002, JAMA.
[17] V. Hasselblad,et al. Predischarge initiation of carvedilol in patients hospitalized for decompensated heart failure: results of the Initiation Management Predischarge: Process for Assessment of Carvedilol Therapy in Heart Failure (IMPACT-HF) trial. , 2004, Journal of the American College of Cardiology.
[18] Christopher M O'Connor,et al. Risk stratification after hospitalization for decompensated heart failure. , 2004, Journal of cardiac failure.